A culture designed to unleash the potential of our people
t has been an over eight-year journey to Mirati’s new home in the Torrey Pines Science Research Park from our humble beginning next to the Montreal airport. The company recently celebrated the opening of its new headquarters, situated in the heart of where innovative science is taking place in San Diego, and is designed for collaboration and innovation. The new headquarters has a fully integrated team of dedicated scientists focused on discovering and developing novel therapeutic strategies directed at targeting mutations causing difficult to treat cancers.
“We are purposefully building a collaborative team to tackle the problem of understanding and treating cancer head on,” says Jamie Christensen, chief scientific officer, Mirati Therapeutics, Inc. “Bringing together unique skillsets across translational research and discovery science, we are exclusively and aggressively focused on programs where existing interventions are unknown or insufficient.”
From seating charts to lab configurations, we are aspiring to maximize collaboration, curiosity, and our drive to do more for patients.
“We have an open office setting providing an opportunity to intermingle different functions and teams,” says Jamie. “Our labs are set up to be integrated so that all disciplines in R&D can benefit from one another and help rapidly share ideas.”
The Mirati culture is designed to unleash the potential of our science and our people by creating an environment that fosters open-mindedness and collaboration as we seek to transform the lives of patients with cancer. The company’s more than 320 employees are uniformly focused on patients by trying to make a difference with our science and in our communities.
“Where we differentiate ourselves is that we believe in advancing innovative oncology medicines focused on areas with significant unmet needs. Our portfolio is built on what is right in front us – we simply accept the challenge,” says Jamie. “The goal is to do things in a way that will help solve specific problems for identifiable patients by targeting the genetic and immunological drivers of cancer.”